After Prasad: What the FDA's Revolving Door Means for Biotech's Regulatory Future

Vinay Prasad is leaving the FDA again. The announcement, confirmed by the Department of Health and Human Services on March 6, 2026, landed with the particular weight that only comes from a story that has been building for months. Prasad, the head of the FDA's Center for Biologics Evaluation and Research, will depart at the end of April, ending a tenure that reshaped how the agency approaches vaccines, gene therapies, and rare disease drug approvals in ways that the industry is still trying to fully understand.

The timing is not incidental. His exit was announced hours after a remarkable episode in which a senior FDA official, widely believed to be Prasad, held an anonymous call with journalists to criticize UniQure and its Huntington's disease gene therapy program. The agency had just told UniQure it would need to run an entirely new sham-controlled trial before seeking approval, a reversal from what the company said it had been told previously. A member of Congress publicly accused the official of violating agency rules and federal law. By the end of the day, Prasad's departure was confirmed.

A Tenure Defined by Turbulence

To understand what Prasad's exit means, it helps to understand what his presence meant. He arrived at CBER in May 2025 as a vocal critic of his predecessor Peter Marks, who had championed regulatory flexibility and overseen the approvals of dozens of cell and gene therapies. Prasad brought a different philosophy: skepticism of surrogate endpoints, insistence on rigorous trial design, and a willingness to publicly challenge the evidentiary basis of drugs that had already been approved or were seeking approval.

In practice, this translated into a series of decisions that surprised and frustrated the biotech industry. Stricter COVID vaccine approval guidelines. A brief refusal to review a Moderna flu shot application before a quick reversal under public pressure. Multiple cases in which companies said the FDA had shifted its guidance mid-development, leaving programs that had been designed around one set of expectations suddenly facing a different set of requirements. Pierre Fabre, RegenxBio, and others found themselves navigating an agency that felt less predictable than it had been.

The UniQure episode crystallized the tension. The company had spent years developing a gene therapy for Huntington's disease, a devastating neurodegenerative condition with no approved treatments. When the FDA told it that a new sham-controlled trial would be required before any approval filing, UniQure called it a U-turn. The agency's decision to then hold an anonymous press call attacking the company's data was, by any measure, an unusual escalation. It was the kind of episode that makes investors nervous and companies question whether the regulatory environment is navigable.

What the Market Is Telling Us

The market's reaction to Prasad's departure was immediate and instructive. Shares of rare disease developers, including UniQure, rose in after-hours trading on the day the news broke. RBC Capital Markets analyst Brian Abrahams described the exit as "likely to be received positively" by the industry. That reaction reflects how much uncertainty Prasad's tenure had introduced into the calculus of biotech development, particularly for companies working in gene therapy and rare pediatric diseases.

But Abrahams also offered a more cautious read. Prasad's departure "perpetuates the regulatory leadership volatility that has kept companies uncertain about their developmental direction and many investors on the sidelines," he wrote. A new CBER director, even one with a more accommodating posture toward rare disease programs, would still be operating within the broader framework that Commissioner Marty Makary has established. The single-trial approval policy, the national priority voucher program, the emphasis on scientific rigor over regulatory tradition: these are Makary's initiatives, and they will outlast Prasad.

The Deeper Problem Is Structural

What the Prasad episode reveals is not simply a personality problem at the FDA. It reveals a structural tension that has been present throughout the Trump administration's approach to drug regulation. On one hand, the administration has pushed for faster approvals, fewer bureaucratic barriers, and a more industry-friendly posture. On the other hand, Prasad's CBER was applying what many companies experienced as a higher evidentiary bar, particularly for gene therapies and rare disease drugs that had historically benefited from regulatory flexibility.

These two impulses are not easily reconciled. The result has been an agency that sends mixed signals: faster reviews through national priority vouchers, but harder questions about whether the underlying data actually supports approval. Companies have found themselves in the uncomfortable position of not knowing which version of the FDA they are dealing with on any given program.

What Comes Next

Makary has said the agency will name a successor before Prasad's departure at the end of April. The choice will matter enormously for the gene therapy and rare disease sectors, which have been most directly affected by CBER's shifting posture. A successor who brings more predictability and clearer communication about evidentiary standards would go a long way toward restoring the confidence that has eroded over the past year.

The deeper question is whether the FDA can stabilize its leadership and its standards at the same time. The revolving door at CBER, which has now seen two directors depart in the span of roughly a year, is itself a source of uncertainty that no individual appointment can fully resolve. For biotech companies planning development programs that span five to ten years, regulatory predictability is not a luxury. It is a prerequisite for investment. Until the FDA can demonstrate that its standards are durable across leadership transitions, that uncertainty will continue to weigh on the sector.

Prasad's departure may be welcomed by many in the industry. But the structural conditions that made his tenure so disruptive remain in place. The next CBER director will inherit both the opportunity to reset the relationship between the agency and the companies it regulates, and the challenge of doing so within a political environment that has not finished reshaping what the FDA is supposed to be.